Analysts Issue Forecasts for ELDN Q1 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Eledon Pharmaceuticals in a research report issued on Wednesday, June 18th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.32) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.27) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.20.

Separately, Wall Street Zen downgraded Eledon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 6th.

Eledon Pharmaceuticals Trading Down 1.1%

NASDAQ:ELDN opened at $2.78 on Thursday. The company has a market capitalization of $166.47 million, a P/E ratio of -1.32 and a beta of -0.17. Eledon Pharmaceuticals has a 12 month low of $2.30 and a 12 month high of $5.54. The business’s 50-day moving average is $3.04 and its 200 day moving average is $3.72.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ELDN. RA Capital Management L.P. bought a new stake in Eledon Pharmaceuticals during the fourth quarter worth approximately $14,693,000. First Light Asset Management LLC bought a new stake in Eledon Pharmaceuticals during the fourth quarter worth approximately $9,595,000. Blue Owl Capital Holdings LP bought a new stake in Eledon Pharmaceuticals during the fourth quarter worth approximately $8,075,000. Sphera Funds Management LTD. increased its stake in Eledon Pharmaceuticals by 96.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company’s stock worth $10,513,000 after acquiring an additional 1,254,298 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. bought a new stake in Eledon Pharmaceuticals during the fourth quarter worth approximately $4,848,000. 56.77% of the stock is owned by institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).